Celldex Therapeutics, Inc. Operating Lease Cost
Celldex Therapeutics, Inc. (CLDX) reported Operating Lease Cost of $2.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-25
- Celldex Therapeutics, Inc. operating lease, cost for the quarter ending 2019-12-31 was $700.00K.
- Celldex Therapeutics, Inc. operating lease, cost for the quarter ending 2019-09-30 was $600.00K.
- Celldex Therapeutics, Inc. operating lease, cost for the quarter ending 2019-06-30 was $500.00K.
- Celldex Therapeutics, Inc. operating lease, cost for the quarter ending 2019-03-31 was $700.00K.
- Celldex Therapeutics, Inc. operating lease, cost for fiscal 2025 was $2.10M, a 5.00% increase from fiscal 2024.
- Celldex Therapeutics, Inc. operating lease, cost for fiscal 2024 was $2.00M, a 5.26% increase from fiscal 2023.
- Celldex Therapeutics, Inc. operating lease, cost for fiscal 2023 was $1.90M, a 0.00% change from fiscal 2022.
- Celldex Therapeutics, Inc. operating lease, cost for fiscal 2022 was $1.90M, a 0.00% change from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.10M 10-K · filed 2026-02-25 | |||
| 2024-12-31 | $2.00M 10-K · filed 2026-02-25 | |||
| 2023-12-31 | $1.90M 10-K · filed 2026-02-25 | |||
| 2022-12-31 | $1.90M 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $1.90M 10-K · filed 2024-02-26 | |||
| 2020-12-31 | $2.30M 10-K · filed 2023-02-28 | |||
| 2019-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.30M derived: sum of 2 quarters · filed 2022-02-28 | $1.80M derived: sum of 3 quarters · filed 2022-02-28 | $2.50M 10-K · filed 2022-02-28 |
| 2019-09-30 | $600.00K 10-Q · filed 2019-11-12 | $1.10M derived: sum of 2 quarters · filed 2019-11-12 | $1.80M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $500.00K 10-Q · filed 2019-08-07 | $1.20M 10-Q · filed 2019-08-07 | ||
| 2019-03-31 | $700.00K 10-Q · filed 2019-05-07 | |||
| 2018-12-31 | $4.00M 10-K · filed 2021-03-29 | |||
| 2017-12-31 | $4.10M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |